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Cellular	in	vitro	HDL-CEC	measurements	
Efflux	experiments	were	performed	for	 the	apoB-depleted	serum	samples	 in	 the	training	data	
set.	 ApoB-containing	 lipoprotein	 precipitation	was	 performed	by	 polyethylene	 glycol	 (PEG)	 to	
obtain	 an	 HDL	 fraction	 for	 cholesterol	 efflux	 studies	 (2-4).	 Briefly,	 40	 parts	 of	 precipitation-
solution	 (20%	PEG	 in	 200	mM	glycine	buffer,	 pH	7.4)	were	 added	 to	 100	parts	 of	 serum	and	
mixed.	PEG	and	glycine	were	purchased	from	Fisher	Scientific.	After	20	min	of	 incubation,	the	
samples	were	 centrifuged	 (10	 000	 x	 g,	 40	min,	 4°C)	 and	 the	 supernatant	 containing	 the	HDL	
fraction	 was	 recovered.	 A	 day	 before	 the	 efflux	 experiments,	 apoB-depleted	 serum	 samples	
were	diluted	to	5.6%	in	MEM-HEPES	(containing	10	mM	HEPES	 in	MEM;	both	purchased	from	
Sigma).		
	
The	cholesterol	efflux	capacity	of	apoB-depleted	serum	(HDL-CEC)	was	measured	by	commonly	
used	 radiolabelled	 cholesterol	 assay	using	and	cAMP-treated	 J774	murine	macrophages	 (2-5).	
The	efflux	experiments	were	performed	with	J774.2	cells	at	37°C	 in	humidified	atmosphere	of	
5%	CO2	and	95%	air.	Briefly,	cells	were	plated	(7	x	10
5	cells/well)	in	96-well	plates,	treated	with	
cAMP	and	 labelled	with	radioactive	cholesterol	 in	serum	free	medium	for	overnight.	Labelling	
medium	 contained	 0.3	 mM	 cAMP	 (8-(4-Clorophenylthio)-cyclic	 AMP,	 Sigma),	 4	 µCi/mL	 [1,2-
3H(N)]-cholesterol	 (Perkin	 Elmer),	 2	 mM	 L-Glutamine	 (Sigma)	 and	 1%	 (v/v)	 penicillin–
streptomycin	 (Sigma)	 in	 DMEM	 (Sigma).	 Next	 day,	 cells	 were	 washed	 with	 MEM-HEPES	 and	
efflux	 assays	 were	 performed.	 To	 start	 the	 efflux	 period,	 0.3	mM	 cAMP	 in	MEM-HEPES	 was	
added	first	on	the	cells,	 following	addition	of	apoB-depleted	serum	samples.	During	the	efflux	
period,	2.8%	apoB-depleted	serum	samples	were	incubated	with	the	labelled	cells	for	6	hour	in	
MEM-HEPES	 containing	 0.15	 mM	 cAMP.	 Thereafter	 medium	 was	 collected	 and	 cell	 lipids	
extracted	 by	 2-propanol.	 Aliquots	 of	 the	 medium	 and	 cell	 extracts	 were	 counted	 for	
radioactivity	 by	 β-counter	 and	 cholesterol	 efflux	 was	 expressed	 as	 percentage	 of	 radioactive	
cholesterol	 released	 in	 the	medium	from	total	 radioactive	cholesterol	present	 in	 the	well.	For	
each	 serum	 sample,	 assays	 were	 done	 as	 parallel	 measurements	 and	 control	 serum	 was	
included	for	all	plates.	Intra-assay	and	inter-assay	CV%	were	3.6%	and	6.1%,	respectively.		
	
Although	cAMP-treated	J774	cell	model	is	most	commonly	used	assay	(6),	there	is	no	universally	
accepted	 method	 for	 HDL-CEC	 measurement	 (7,8).	 In	 general,	 these	 assays	 vary	 in	 several	
components,	 such	 as	 cholesterol	 label	 used	 (fluorescent	or	 radioactive),	 cell	 type,	 cholesterol	
loading	 or	 labelling	 and	 cell	 treatment	 with	 inducers	 (6,7).	 To	 clarify	 in	 vitro	 HDL-CEC	
measurement	 behind	 the	 NMR-based	 HDL-CEC	 assay,	 we	 documented	 the	 main	 variable	
components	 to	 Supplemental	 Table	 1.	 Variations	 in	 these	 components	 may	 affect	 to	 the	
contribution	of	each	efflux	pathway	 in	efflux	assays.	For	example,	 cholesterol	 loading	 induces	
ABC-transporters	 (6),	 cAMP-treatment	 stimulates	 ABCA1	 expression	 (4,9),	 ACAT	 inhibitor	
prevents	labelled	cholesterol	to	accumulate	as	cholesterol	ester	(6)	and	it	may	also	enhance	the	
expression	of	ABCA1	in	cells	(10,11).		
	
The	 efflux	 pathways	 in	 radioactive	 cholesterol	 labelled	 cAMP-treated	 J774	 cells	 are	 ABCA1,	
ABCG1,	SR-B1,	passive	diffusion	and	possible	undiscovered	pathways	(4).	In	this	cell	model,	the	
majority	 of	 cholesterol	 efflux	 seems	 to	 be	 mediated	 through	 diffusion,	 either	 passively	 with	
minor	contribution	from	ABCG1	and	SR-B1,	and	possible	unknown	pathways	(4,6).	However,	the	
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role	of	ABCA1	pathway	varies	depending	mainly	on	cAMP-treatment	conditions,	since	this	efflux	
receptor	 is	 inducible	 by	 cAMP	 (4,9).	 Therefore	 we	 determined	 the	 percentage	 of	 cAMP-
dependent	 efflux	 in	 our	 cell	model.	 cAMP-dependent	 efflux	 =	 efflux	%	with	 cAMP-treatment	
minus	 efflux	%	without	 cAMP-	 treatment	 (12).	 For	 this	measurement,	we	 performed	 parallel	
efflux-analysis	without	cAMP-treatment	simultaneously	 in	same	efflux-assay	with	 in	vitro	HDL-
CEC	measurement.	cAMP-dependent	efflux	was	median	of	7%	(interquartile	range:	5%-10%,	n	=	
199)	 from	 total	 cholesterol	 efflux,	 Indicating	 that	 minority	 of	 efflux	 was	 mediated	 through	
ABCA1	 transporter	 in	 our	 cell	 model	 and	 majority	 of	 the	 efflux	 was	 accounted	 by	 diffusion	
(either	 passively	 or	 facilitated	 by	 ABCG1	 (13)	 and	 SR-B1	 (13))	 or	 undiscovered	 pathways.	
However,	difference	between	cAMP-treated	and	non-treated	cells	is	really	a	robust	measure	for	
ABCA1-mediated	efflux:	 cAMP-dependent	 efflux	do	not	 correlate	well	with	ABCA1-dependent	
(probucol	 inhibitable)	 efflux	 (r=0.56)	 (14).	 In	 addition,	 cAMP-treatment	 in	 J774	 cells	 causes	
changes	in	relative	contributions	of	efflux	pathways	for	total	cholesterol	efflux),	i.e.	contribution	
of	SR-B1	pathway	decreases	and	ABCA1	increases	(15).	Roughly,	ABCA1-dependent	efflux	seems	
to	be	about	50%	higher	than	cAMP-dependent	efflux	(15).	Therefore,	we	assumed	that	ABCA1-
dependent	efflux	in	our	cell	model	is	approximately	two	times	cAMP-dependent	efflux	(median	
14%	(interquartile	range:	10%-20%)).	ABCA1-dependent	efflux	seems	to	contribute	 for	30%	to	
40%	of	the	total	efflux	in	cAMP-treated	J774	cells	(6),	 indicating	that	in	our	cell	model	ABCA1-
dependent	 efflux	 is	 lower	 than	 generally	 described.	 On	 the	 other	 hand,	 many	 studies	 using	
cAMP-treated	 J774	 cells	 do	not	 describe	 the	 contribution	of	ABCA1-dependent	 efflux	 in	 their	
assays	 (16,17,18,19),	 thus	 it	 remains	 largely	 unknown.	 However,	 although	 ABCA1-dependent	
efflux	 probably	 varies	 between	 studies	 using	 radiolabelled	 cholesterol	 assay	 in	 cAMP-treated	
J774	cells,	diffusion-driven	pathways	remain	the	main	contributing	efflux	mechanisms	in	these	
cells.	
	
Lipoprotein	quantification	and	HDL-CEC	modelling	from	the	serum	NMR	spectra	
Lipoprotein	profiling	by	proton	NMR	spectroscopy	is	currently	well	established	and	was	done	as	
previously	 described	 (20-22).	 A	 computationally	 more	 efficient	 modification	 of	 the	 Bayesian	
approach	 than	we	 presented	 previously	 (23)	was	 applied.	 The	 lipoprotein	 subclasses	 in	NMR	
spectroscopy	 are	 defined	 by	 particle	 size:	 potential	 chylomicrons	 and	 the	 largest	 very-low-
density	 lipoprotein	particles	(XXL-VLDL;	average	particle	diameter	≥75	nm);	five	different	VLDL	
subclasses,	 i.e.	very	 large	 (average	particle	diameter	64.0	nm),	 large	 (53.6	nm),	medium	(44.5	
nm),	small	(36.8	nm)	and	very	small	VLDL	(31.3	nm);	intermediate-density	lipoprotein	(IDL;	28.6	
nm);	and	three	LDL	subclasses,	i.e.	large	(25.5	nm),	medium	(23.0	nm)	and	small	LDL	(18.7	nm).	
The	 four	 size-specific	HDL	 subclasses	are	very	 large	 (14.3	nm),	 large	 (12.1	nm),	medium	 (10.9	
nm)	and	small	HDL	(8.7	nm)	(21,22).		
	
Similarly,	 selected	 regions	 of	 the	 NMR	 spectra	 (containing	 the	 main	 resonances	 of	 the	
lipoprotein	 lipid	 constituents)	 were	 linked,	 via	 a	 linear	 Bayesian	 model	 (20,23),	 to	 the	
independently	 assayed	 HDL-CEC	 estimates	 from	 the	 cellular	 in	 vitro	 measurements	 in	 the	
training	data	set.	A	good	correspondence	between	the	NMR-based	and	the	in	vitro	determined	
HDL-CEC	estimates	was	established	with	a	cross-validation	R2	=	0.83;	Supplemental	Fig.	2	 (see	
also	 Bland-Altman	 plot	 in	 Supplemental	 Fig.	 3).	 The	 analytical	 correspondence	 is	 similar	 to	
those	 between	NMR-based	 lipoprotein	 lipid	measures	 and	 the	 corresponding	measures	 from	
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traditional	 clinical	 chemistry	assays	 (21,23).	 In	addition,	 similar	 correspondence	has	also	been	
indicated	between	NMR-based	and	clinical	biochemistry	for	eight	routinely	measured	traits	(24).	
This	established	 linear	Bayesian	model	 (together	with	the	 lipoprotein	profiling)	was	applied	 in	
the	FINRISK97	cohort	for	all	the	7,603	serum	NMR	spectra	to	estimate	corresponding	HDL-CEC	
values;	the	distribution	of	these	HDL-CEC	estimates	is	illustrated	in	Supplemental	Fig.	10.	
	
Statistical	analysis	
For	parametric	statistics,	outliers	for	each	quantitative	measure	were	defined	as	values	that	lie	
over	 4	 times	 higher	 or	 lower	 than	 the	 interquartile	 range.	 In	 FINRISK97,	 74	 outliers	 were	
removed	from	the	statistical	analyses	in	the	case	of	HDL-CEC.	In	addition,	for	the	analysis	of	the	
association	 of	NMR-based	HDL-CEC	 estimates	with	 incident	 first	 CHD	 events,	 individuals	with	
prevalent	CHD	events	 (n=203)	and	missing	data	and	outliers	 in	study	variables	 (n	=	110)	were	
removed	leaving	complete	data	for	7,290	 individuals	and	574	 incident	CHD	events	(defined	as	
fatal	 or	 nonfatal	 myocardial	 infraction,	 cardiac	 revascularization,	 or	 unstable	 angina)	 for	 the	
analysis.	For	the	analysis	of	the	association	of	NMR-based	HDL-CEC	estimates	with	incident	first	
CVD	 events	 (defined	 as	 fatal	 or	 nonfatal	 myocardial	 infraction,	 ischemic	 stroke,	 cardiac	
revascularization,	 or	 unstable	 angina),	 individuals	 with	 prevalent	 CVD	 events	 (n	 =	 263)	 and	
missing	data	and	outliers	 in	study	variables	 (n	=	109)	were	removed	 leaving	complete	data	of	
7,231	individuals	and	789	incident	CVD	events	for	the	analysis.	The	median	follow	up	time	was	
14.8	years.	Baseline	characteristics	are	presented	in	Supplemental	Table	2.	For	non-parametric	
statistics	(Spearman’s	rank	correlation),	all	participants	with	complete	data	were	used.	
	
Statistical	analyses	were	performed	by	R	statistical	software	version	3.3.3.	The	survival	analysis	
was	performed	by	R	packages	 survival,	 survminer	 and	 SurvMisc.	 The	 associations	 of	HDL-CEC	
estimates	 with	 incident	 CHD	 events	 were	 analysed	 by	 Cox	 proportional	 hazard	 regression	
models.	 For	 these	 analyses	 skewed	 variables	 were	 transformed	 for	 normality:	 triglyceride	
concentrations	 and	 BMI	 were	 log-transformed	 and	 alcohol	 intake	 log1p-transformed	 (loge	
(1+x)).	The	fully	adjusted	model	included	age,	sex,	geographical	region,	diabetes,	mean	arterial	
blood	pressure,	blood	pressure	treatment,	smoking,	log	BMI,	total	cholesterol,	log	triglycerides,	
lipid	lowering	treatment	and	concentrations	of	HDL	cholesterol,	HDL	particle	and	apolipoprotein	
A1.	A	key	aim	was	to	see	if	the	NMR-based	HDL-CEC	estimates	would	show	similar	associations	
to	previous	large-scale	epidemiological	studies.	Therefore,	we	performed	analyses	as	similar	to	
those	 used	 by	 Rohatgi	 et	 al	 (1)	 and	 Saleheen	 et	 al	 (2),	 including	 using	 the	 same	 statistical	
adjustments,	and	calculated	the	hazard	ratios	for	incident	CHD	events	for	tertiles	and	quartiles	
using	the	bottom	one	as	the	reference.	 In	addition,	analyses	were	performed	per	1-SD	higher	
HDL-CEC		(see	Supplemental	Table	5).		
	
The	ability	of	NMR-based	HDL-CEC	estimates	to	improve	CHD	risk	prediction	beyond	traditional	
risk	factors	and	HDL-C	was	assessed	in	well-calibrated	models	(Supplemental	Fig.	7)	by	using	C-
statistics,	 continuous	 net	 reclassification	 index	 (NRI)	 (25,26)	 and	 integrated-discrimination-
improvement	 index	 (IDI)	 (26).	To	evaluate	model	calibration,	predicted	and	observed	risk	was	
assessed	 by	 R	 package	 rms.	Hosmer-Lemeshow	 test	was	 calculated	 by	 R	 package	MKmisc.	 C-
statistics	was	calculated	by	R	package	survcomp	and	NRI	&	IDI	by	the	R	package	survIDINRI.	
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Associations	 between	 variables	 were	 assessed	 by	 partial	 correlation	 (Spearman)	 adjusted	 for	
age	and	sex.	Partial	correlation	coefficients	(95%	CI	and	p-value)	were	calculated	by	R	package	
RVAideMemoire	using	500	replications	to	compute	95%	confidence	intervals	by	bootstrapping.	
Two-sided	P-value	was	computed	through	the	asymptotic	t	approximation.	Due	to	overall	cross-
correlation	nature	of	HDL	subclass	data,	we	made	corrections	for	multiple	tests	when	analysing	
associations	 of	 HDL-related	 measured	 with	 HDL	 subclass	 data	 by	 evaluating	 the	 number	 of	
independent	tests	using	principal	component	analysis.	Seven	principal	components	were	able	to	
explain	99%	of	variation	in	the	FINRISK97	HDL	subclass	data.	Due	to	this,	P	<	0.007	(0.05/7)	was	
used	to	denote	statistical	significance	in	these	analyses.	
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SUPPLEMENTAL	FIGURES	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Supplemental	 Fig.	 1:	Overview	of	 the	 study.	 (a)	NMR	spectra	and	 the	 in	vitro	HDL-CEC	were	
analysed	in	training	data	subjects	(online	Methods;	Training	data).	(b)	A	mathematical	model	for	
the	quantitative	relationship	between	the	NMR	spectra	and	the	 in	vitro	HDL-CEC	assay	values	
was	constructed	(online	Methods;	Lipoprotein	quantification	and	HDL-CEC	modelling	from	the	
NMR	 spectra).	 This	 model	 enables	 HDL-CEC	 to	 be	 estimated	 directly	 from	 the	 serum	 NMR	
spectra.	(c)	NMR-based	HDL-CEC	values	were	estimated	in	the	FINRISK97	cohort	from	the	NMR	
spectra	and	used	in	the	statistical	analyses	to	assess	the	associations	of	HDL-CEC	with	CHD	and	
CVD	outcomes.	
	
(a)	Training	data	(n	=	199)	
Measurement	of	in	vitro	HDL-CEC	and	NMR	spectra	
(b)	Bayesian	modelling	and		cross-validanon	of	NMR-based	HDL-CEC	in	
training	data	(n	=	199)	
(c)	Esnmanon	of	NMR-based	HDL-CEC	in	FINRISK97	(n	=	7,603)	
Associanons	with	incident	CHD	and	CVD	events	
Correlanons	with	various	clinical	and	lipid	traits	
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Supplemental	Fig.	2:	Set-up	and	validation	of	the	NMR-based	HDL-CEC	assay	(n	=	199).	In	vitro	
HDL-CEC	values	were	measured	by	cAMP-treated	 J774	cells	and	compared	 to	HDL-CEC	values	
estimated	from	the	NMR	spectra.	The	solid	dots	are	averages	and	the	error	bars	denote	the	95%	
confidence	 intervals	 for	 the	 estimates	 using	 1,000	 bootstrap	models	 with	 randomly	 selected	
training	samples.	Dashed	line	marks	the	1:1	relationship.	
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Supplemental	 Fig.	3:	Bland-Altman	plot	 for	 the	difference	between	NMR	based	and	 in	vitro	
measured	 HDL-CEC	 (n	 =	 199).	 In	 vitro	 HDL-CEC	 values	were	measured	by	 cAMP-treated	 J774	
cells	 and	 compared	 to	HDL-CEC	 values	 estimated	 from	 the	NMR	 spectra.	 Solid	 line	 show	 the	
mean	bias	between	NMR-based	and	 in	vitro	measured	HDL-CEC	and	dotted	 line	represent	the	
limits	of	agreement	(±	1.96	SD).	
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Supplemental	Fig.	4:	A	non-adjusted	cubic	 spline	of	 the	continuous	 logarithmic	hazard	 ratio	
(HR)	for	CHD	across	HDL-CEC	values	in	the	FINRISK97	cohort	(events	=	574;	n	=	7,290).	Smooth	
LnHR	for	continuous	NMR-based	HDL-CEC	was	calculated	by	R	package	smoothHR.	
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Supplemental	Fig.	5:	Kaplan-Meier	curves	and	hazard	ratios	for	incident	CVD	events	according	
to	 the	 quartiles	 of	 HDL-CEC.	 HR	was	 calculated	 by	 Cox	 proportional	 hazard	model	 with	 the	
lowest	 quartile	 of	 HDL-CEC	 as	 a	 reference.	 HR	 was	 adjusted	 for	Model	 1	 and	 in	 addition	 to	
Model	2.		
ATraditional	 risk	 factors	 included	 age,	 sex,	 geographical	 region,	 diabetes,	mean	 arterial	 blood	
pressure,	blood	pressure	treatment,	smoking,	 log	BMI,	total	cholesterol,	 log	TG,	 lipid	 lowering	
treatment.	
HDL-CEC;	NMR-based	HDL-mediated	cholesterol	efflux	estimate,	HDL-C;	high-density	lipoprotein	
cholesterol	 concentration,	 apoA1;	 apolipoprotein	 A1	 concentration,	 TG;	 triglyceride	
concentration,	 HDL-P;	 total	 high-density	 lipoprotein	 particle	 concentration	 (a	 sum	 of	 the	
individual	HDL	subclass	particle	concentrations).	
Model	1:	Traditional	risk	factors,	HDL-C		
Model	2:	Traditional	risk	factors,	HDL-C,	HDL-P	and	apoA1	
†Additional	statistics	for	Log-rank	test	(chi-squared	=	18.23,	df	=	3,	two-sided)	
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Supplemental	Fig.	6:	Association	of	HDL-CEC	for	incident	CHD	events	stratified	by	subgroups	in	
FINRISK97.	 Hazard	 ratio	 (HR)	 for	 NMR-based	 HDL-CEC	 was	 calculated	 by	 Cox	 proportional-
hazard	model	by	quartiles	with	the	lowest	quartile	as	a	reference.	HR	of	quartiles	are	shown	for	
comparison	of	top	quartile	to	bottom	quartile.	
HDL-CEC;	NMR-based	HDL-mediated	cholesterol	efflux	estimate,	HDL-C;	high-density	lipoprotein	
cholesterol	 concentration,	 apoA1;	 apolipoprotein	 A1	 concentration,	 HDL-P;	 total	 high-density	
lipoprotein	particle	concentration	(a	sum	of	the	individual	HDL	subclass	particle	concentrations).	
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Supplemental	Fig.	7:	Calibration	plots	between	predicted	and	observed	risk	in	FINRISK97	(n	=	
7,291;	 574	 CHD	 events).	 Predicted	 risk	 was	 calculated	 for	 (a)	 reference	 model	 containing	
traditional	 risk	 factors	 and	HDL-C	 and	 (b)	 study	model	with	 additionally	 included	NMR-based	
HDL-CEC.	 Data	 are	 predicted	 risk	 (survival	 probability)	 deciles	 (n	 =	 729	 per	 group)	 and	
corresponding	Kaplan-Meier	estimates	for	observed	risk.	Calibration	was	analysed	by	Hosmer-
Lemeshow	goodness-of-fit	test	between	predicted	and	observed	risk	(n	=	20,	df	=	8).	
Traditional	 risk	 factors	 (TRF)	 included	 age,	 sex,	 geographical	 region,	 diabetes,	 mean	 arterial	
blood	pressure,	blood	pressure	treatment,	smoking,	 log	BMI,	 total	cholesterol,	 log	 triglyceride	
concentration,	lipid	lowering	treatment.	
HDL-CEC;	NMR-based	HDL-mediated	cholesterol	efflux	estimate,	HDL-C;	high-density	lipoprotein	
cholesterol	concentration.	
Dashed	grey	line	is	for	1:1	relationship.		
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Supplemental	Fig.	8:	Associations	of	HDL-CEC	and	related	measures	with	HDL	subclass	particle	
concentrations	 in	 the	 FINRISK97	 cohort	 and	 in	 the	 training	 data	 stratified	 by	 sex.	 The	
FINRISK97	data	are	NMR-based	HDL-CEC	estimates	and	the	training	data	are	from	in	vitro	HDL-
CEC	measurements.	HDL	subclasses	were	measured	by	NMR	spectroscopy	and	are	defined	by	
particle	 size	 as	 follows:	 XL-HDL;	 very	 large	 (average	 particle	 diameter	 14.3	 nm),	 L-HDL;	 large	
(12.1	nm),	M-HDL;	medium	(10.9	nm)	and	S-HDL;	small	HDL	(8.7	nm)	(21).		
HDL−CEC
−0.2 0.2 0.6 1
1XL−HDL−P
2L−HDL−P
3M−HDL−P
4S−HDL−P
S−HDL−P
M−HDL−P
L−HDL−P
XL−HDL−P
Male (n = 3,776)
Female (n = 3,821)
HDL−C
−0.2 0.2 0.6 1
Total HDL−P
−0.2 0.2 0.6 1 −0.2 0.2 0.6 1
HDL−CEC
−0.2 0.2 0.6 1
1XL−HDL−P
2L−HDL−P
3M−HDL−P
4S−HDL−P
S−HDL−P
M−HDL−P
L−HDL−P
XL−HDL−P
Male (n = 108)
Female (n = 90)
HDL−C
−0.2 0.2 0.6 1
P−value ? 0.007
HDL−CEC
HDL−C
Total HDL−P
apoA1
Total HDL−P
−0.2 0.2 0.6 1
P−value ? 0.007
HDL−CEC
HDL−C
Total HDL−P
apoA1
−0.2 0.2 0.6 1
?pearman rank correlation coefficient (95% CI) adjusted for age 
apoA1
apoA1
?????????
?????????????
	 –	14	(29)	–		
	
	
	
Supplemental	 Fig.	 9:	 Associations	 of	 HDL-related	 measures	 with	 HDL	 subclass	 lipid	
concentrations	in	the	FINRISK97	cohort	(n	=	7,597).	Data	are	Spearman	correlation	coefficients	
adjusted	for	age	and	sex.	HDL	subclasses	were	measured	by	NMR	spectroscopy	and	are	defined	
by	particle	size	as	follows:	XL-HDL;	very	large	(average	particle	diameter	14.3	nm),	L-HDL;	large	
(12.1	nm),	M-HDL;	medium	(10.9	nm)	and	S-HDL;	small	HDL	(8.7	nm)	(21).	P-value	was	adjusted	
for	multiple	 testing	 by	 using	 principal	 component	 analysis	 (online	Methods).	 HDL-CEC;	 NMR-
based	 HDL-mediated	 cholesterol	 efflux	 estimate,	 HDL-C;	 high-density	 lipoprotein	 cholesterol	
concentration,	 apoA1;	 apolipoprotein	 A1	 concentration,	 HDL-P;	 total	 high-density	 lipoprotein	
particle	concentration	(a	sum	of	the	individual	HDL	subclass	particle	concentrations).	
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Supplemental	Fig.	10:	Distribution	of	HDL-CEC	values	in	the	FINRISK97	cohort	(n	=	7,529).	(a)	
Boxplot	of	HDL-CEC	with	center	 line,	median;	box	 limits,	upper	and	 lower	quartiles;	whiskers,	
1.5x	 interquartile	 range;	points,	 values	 that	 lie	over	1.5x	 interquartile	 range.	 (b)	Histogram	of	
HDL-CEC.	 Outliers	 (n	 =	 74)	 were	 removed	 as	 explained	 in	 Supplemental	 methods,	 Statistical	
analysis.	
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Supplemental	Fig.	11:	Spearman	correlations	between	 the	NMR	spectral	profile	and	various	
key	HDL-related	measures	 in	 the	 training	data	 set	 (n	=	199).	A	colour	bar	for	the	correlation	
coefficients	is	shown	on	the	top.	Only	correlations	with	P	<	0.001	are	shown	in	colour.	The	HDL-
CEC	 marked	 ‘in	 vitro’	 refers	 to	 values	 measured	 by	 cAMP-treated	 J774	 cells	 and	 HDL-CEC	
marked	‘NMR’	refers	to	values	estimated	from	the	NMR	spectra	by	the	new	method.	HDL	refers	
to	 high-density	 lipoprotein,	 LDL	 to	 low-density	 lipoprotein,	 ApoA1	 to	 apolipoprotein	 A1,	 C	 to	
cholesterol,	P	to	particle	and	TG	to	triglyceride	concentration.	XL,	L,	M	and	S	refer	to	very	large	
(average	particle	diameter	14.3	nm),	large	(12.1	nm),	medium	(10.9	nm)	and	small	(8.7	nm)	HDL	
subclasses,	 respectively	 (22).	 The	 key	 proton	 NMR	 resonances	 for	 lipoprotein	 lipids	 are	
illustrated	via	a	representative	spectrum	of	human	serum.	The	assignments	refer	to	fatty	acids	
in	 triglycerides,	 cholesterol	 compounds	and	phospholipids	 in	 various	 lipoprotein	particles,	 the	
cholesterol	backbone	–C(18)H3	and	the	–N(CH3)3	groups	of	surface	phospholipids.	Importantly,	
the	correlation	profiles	for	both	HDL-CEC	measures	are	very	similar,	however	they	differ	clearly	
from	the	correlation	profiles	for	other	HDL-related	measures.	As	would	be	expected	based	on	
the	results	in	Supplemental	Figures	8	and	9,	the	spectral	associations	of	the	HDL-CEC	measures	
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are	stronger	for	the	spectral	regions	representing	larger	HDL	particles,	i.e.,	towards	higher	ppm	
values	in	each	main	resonance	area,	e.g.,	the	methyl	-CH3	or	methylene	(-CH2-)n	signals	(27-29),	
with	associations	missing	for	the	spectral	regions	mainly	representing	the	smallest	HDL	particles	
(see	 the	 association	 profile	 for	 S-HDL-P	 for	 comparison).	 In	 addition,	 the	 strongest	 spectral	
correlations	for	the	key	cholesterol	measures,	HDL-C	and	LDL-C,	as	well	as	for	triglycerides,	the	
majority	 of	 which	 are	 transported	 in	 very-low-density	 lipoprotein	 (VLDL)	 particles,	 are	
positioned	as	 expected,	 i.e.,	 in	 the	order	of	 decreasing	particle	 size	 (VLDL,	 LDL	 and	HDL),	 the	
larger	particles	on	higher	ppm	values	in,	e.g.,	the	(-CH2-)n	and	in	the	-CH3	resonance	regions	(27-
29).	The	same	expected	size	versus	chemical	shift	 tendency	 is	seen	for	 the	correlations	 in	 the	
case	of	the	HDL	subclass	particle	concentrations.	ApoA-I	correlations	show	a	lot	of	similarly	to	
those	of	HDL-C,	except	does	not	show	the	negative	associations	 to	 triglycerides	as	HDL-C	and	
the	 two	 largest	HDL	 subclasses	 (that	 reflect	 the	well-known	 reverse	association	of	HDL-C	and	
triglycerides	 in	 the	 circulation).	 The	 total	 serum	 C	 and	 LDL-C	 correlations	 span	 the	 widest	
spectral	 regions,	 excluding	 those	 with	 the	 strongest	 associations	 with	 serum	 TG.	 All	 the	
association	 are	 along	 the	 lines	 expected	 on	 the	 basis	 of	 lipoprotein	 particle	 structure	 and	
composition	(28,29).	However,	 it	should	be	noted	that	the	information	in	the	NMR	spectra	on	
lipoprotein	 subclasses	 and	 lipids	 is	 overlapping	 and	 complex.	 Thus,	 detailed	 molecular	
interpretation	on	the	basis	of	the	NMR-based	HDL-CEC	measure	is	not	possible	based	on	these	
data.	 For	more	 discussion	 on	 the	 spectral	 issues	 and	 data	 analyses,	 the	 reader	 is	 referred	 to	
earlier	works	with	a	more	spectroscopic	focus	(20-23,27-29).	
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SUPPLEMENTAL	TABLES	
	
	
Supplemental	Table	1:	Details	of	in	vitro	HDL-CEC	assay.	
Label		 Cells	 Cholesterol	
loading	/	
labelling	
treatment	 Possible	cholesterol	
efflux	pathways	
present	
Tritium-labelled	
free	cholesterol	
J774.2	 labelled	 cAMP	
ACAT	inhibitor	not	
used.	
Majority	of	efflux	
accounted	by	
diffusion	(aqueous	
diffusion,	minor	
contributes	from	
SR-B1	and	possible	
ABCG1).	ABCA1	has	
minor	role.		
cAMP;	8-(4-Clorophenylthio)-cyclic	AMP.	
ACAT;	acetyl-Coenzyme	A	acetyltransferase.	
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Supplemental	Table	2:	Characteristics	of	training	data	and	the	FINRISK97	cohort.	
Variable	 Training	data		
(n	=	199)	
																		FINRISK97	
																	(n	=	7,290)b																		
Women,	%		 46		 50	 7,603	
Age	(years)	 49.5	(36.0-58.0)	 48	(37-59)	 7,598	
Estimated	HDL-CEC	(%)	 20.1	(19.4-20.9)	 21.8	(20.7-23.4)	 7,603	
In	vitro	HDL-CEC	(%)	 20.0	(19.1-21.1)	 -	 -	
Total	cholesterol	(mg/dl)c	 166	(147-190)	 205	(174-232)	 7,602	
LDL	cholesterol	(mg/dl)c	 58	(46-70)	 74	(58-89)	 7,602	
HDL	cholesterol	(mg/dl)c	 54	(46-66)	 58	(50-70)	 7,602	
Total	HDL	particle	concentration	
(µmol/l)	
8.0	(7.3-8.9)	 8.4	(7.5-9.3)	 7,603	
Trigycerides	(mg/dl)d	 106	(80-142)	 106	(71-142)	 7,602	
Apolipoprotein	A1	(g/l)	 1.5	(1.4-1.7)	 1.6	(1.4-1.7)	 7,602	
Apolipoprotein	B	(g/l)	 0.9	(0.7-1.0)	 1.0	(0.8-1.1)	 7,602	
VLDL	dimension	(nm)	 36.9	(35.7-38.0)	 35.2	(34.6-36.0)	 7,602	
LDL	dimension	(nm)	 23.6	(23.5-23.6)	 23.7	(23.6-23.8)	 7,602	
HDL	dimension	(nm)	 10.1	(9.9-10.3)	 10.2	(10.0-10.4)	 7,602	
Mean	arterial	blood	pressure	(mm	Hg)	 -	 108.0	(98.5-118.5)	 7,600	
Alcohol	consumption	(g/weeka)	 -	 24.9	(3.8-75.4)	 7,418	
BMI	 	 26.1	(23.5-29.1)	 7,594	
Waist	to	hip	ratio	 -	 0.9	(0.8-0.9)	 7,567	
Current	smokers,	%		 	 23		 7,603	
Anti-hypertensive	medication,	%		 -	 13		 7,603	
Lipid-lowering	medication,	%		 -	 4	 7,603	
Diabetes	prevalence,	%		 	 6		 7,598	
Incident	CHD	events		 -	 574	 7,290	
					Follow	up	time	(years)	 -	 14.8	(14.8-14.9)	 7,290	
Incident	CVD	events		 -	 789	 7,231	
					Follow	up	time	(years)	 -	 14.8	(14.8-14.9)	 7,231	
Data	are	median	(25th	and	75th	percentiles)	or	percentage,	when	appropriate.	
In	vitro	HDL-CEC	was	measured	in	cAMP-treated	J774	cells	as	described	in	methods.	
aAverage	alcohol	consumption	during	last	12	months.	
bThe	number	of	individuals	in	the	analysis	of	the	incident	CHD	events.	
n;	number	of	subjects.	
cTo	get	from	mg/dl	to	mmol/l	multiply	by	0.02586	
dTo	get	from	mg/dl	to	mmol/l	multiply	by	0.01129	
CVD;	cardiovascular	disease	(defined	as	fatal	or	nonfatal	myocardial	infraction,	ischemic	stroke,	
cardiac	revascularization,	or	unstable	angina)	(30-32)		
CHD;	 coronary	 heart	 disease	 ((defined	 as	 fatal	 or	 nonfatal	 myocardial	 infraction,	 cardiac	
revascularization,	or	unstable	angina))	
	“-“	indicates	a	variable	not	present	in	the	training	dataset.	
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Supplemental	 Table	 3:	 Association	 of	 NMR-based	 HDL-CEC	 with	 incident	 CHD	 events	 in	
FINRISK97	(n	=	7290,	events	=	574).	
Adjustment	 HR	(95%	CI)	
4th	vs	1st	quartile	
HR	(95%	CI)	
1-SD		
None	 0.63	(0.50-0.80)	 0.84	(0.77-0.91)	
Age	+	sex	 0.65	(0.51-0.83)	 0.84	(0.78-0.91)	
TRF	 0.64	(0.51-0.82)	 0.84	(0.77-0.91)	
TRF	+	HDL-C	 0.69	(0.54-0.87)	 0.86	(0.79-0.93)	
TRF	+	HDL-C	+	apoA1	 0.73	(0.57-0.94)	 0.88	(0.80-0.96)	
TRF	+	HDL-C	+	apoA1	+	HDL-P	 0.74	(0.57-0.95)	 0.88	(0.80-0.96)	
Hazard	ratio	was	calculated	by	Cox	proportional	hazard	model	with	the	lowest	quartile	of	HDL-
CEC	as	a	reference	or	by	continuous	variable	per	1-SD	higher	HDL-CEC.	
Traditional	 risk	 factors	 (TRF)	 included	 age,	 sex,	 geographical	 region,	 diabetes,	 mean	 arterial	
blood	 pressure,	 blood	 pressure	 treatment,	 smoking,	 log	 BMI,	 total	 cholesterol,	 log	 TG,	 lipid	
lowering	treatment.	
HDL-CEC;	NMR-based	HDL-mediated	cholesterol	efflux	estimate,	HDL-C;	high-density	lipoprotein	
cholesterol	 concentration,	 apoA1;	 apolipoprotein	 A1	 concentration,	 TG;	 triglyceride	
concentration,	 HDL-P;	 total	 high-density	 lipoprotein	 particle	 concentration	 (a	 sum	 of	 the	
individual	HDL	subclass	particle	concentrations).	
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Supplemental	Table	4:	Association	of	NMR-based	HDL-CEC	with	hard	atherosclerotic	cardiovascular	disease	in	FINRISK97.		
Results	by	 Adjustments	 HR	(95%CI)	 HR	(95%CI)	 HR	(95%CI)	
	 	 Hard	atherosclerotic	
Cardiovascular	disease		
Myocardial	
infraction	
Stroke	
	
	 	 (events=559;	n=7282)	 (events=305;	n=7346)	 (events=347;	n=7420)	
4th	vs	1st	
quartile	
none	 0.79	(0.63-1.00)	 0.65	(0.47-0.90)	 0.85	(0.64-1.13)	
Age	+	sex	 0.77	(0.61-0.97)	 0.65	(0.46-0.90)	 0.82	(0.61-1.10)	
	 TFR	 0.78	(0.61-0.98)	 0.64	(0.46-0.90)	 0.85	(0.63-1.14)	
	 TRF	+	HDL-C	 0.82	(0.65-1.04)	 0.69	(0.50-0.97)	 0.88	(0.66-1.19)	
	 TRF	+	HDL-C	+	ApoA1	 0.87	(0.67-1.12)	 0.76	(0.53-1.08)	 0.88	(0.64-1.21)	
	
	
TRF	+	HDL-C	+	ApoA1	+	HDL-P	 0.87	(0.68-1.12)	 0.76	(0.53-1.08)	 0.89	(0.64-1.22)	
1-SD	 none	 0.93	(0.85-1.01)	 0.86	(0.77-0.97)	 0.96	(0.86-1.07)	
	 Age	+	sex	 0.91	(0.84-0.99)	 0.85	(0.76-0.96)	 0.94	(0.84-1.04)	
	 TFR	 0.91	(0.84-0.99)	 0.85	(0.76-0.95)	 0.95	(0.85-1.06)	
	 TRF	+	HDL-C	 0.93	(0.85-1.01)	 0.87	(0.78-0.98)	 0.96	(0.86-1.07)	
	 TRF	+	HDL-C	+	ApoA1	 0.95	(0.87-1.04)	 0.91	(0.80-1.02)	 0.96	(0.86-1.08)	
	 TRF	+	HDL-C	+	ApoA1	+	HDL-P	 0.95	(0.87-1.04)	 0.90	(0.80-1.02)	 0.97	(0.86-1.09)	
Hazard	ratio	(HR)	for	NMR-based	HDL-CEC	was	calculated	by	Cox	proportional-hazard	model	by	quartiles	and	as	continuous	measure	
(per	1-SD	higher	HDL-CEC).	HR	of	quartiles	are	shown	for	comparison	of	top	per	bottom.	Hard	atherosclerotic	cardiovascular	disease	
was	defined	as	a	combination	of	fatal	and	non-fatal	myocardial	infarction	or	stroke,	which	ever	occurred	first.	For	the	analysis	of	the	
association	 of	 NMR-based	 HDL-CEC	 estimates	 with	 incident	 hard	 atherosclerotic	 cardiovascular	 disease	 events,	 individuals	 with	
prevalent	hard	atherosclerotic	cardiovascular	disease	events	(n	=	212)	and	missing	data	and	outliers	in	study	variables	(n	=	109)	were	
removed	 leaving	 complete	 data	 for	 7282	 individuals	 and	 559	 incident	 hard	 atherosclerotic	 cardiovascular	 disease	 events	 for	 the	
analysis.	For	the	analysis	of	the	association	of	NMR-based	HDL-CEC	estimates	with	incident	Stroke	events,	individuals	with	prevalent	
stroke	 events	 (n	 =	 74)	 and	missing	 data	 and	outliers	 in	 study	 variables	 (n	 =	 109)	were	 removed	 leaving	 complete	 data	 for	 7,420	
individuals	and	374	incident	stroke	events	for	the	analysis.	For	the	analysis	of	the	association	of	NMR-based	HDL-CEC	estimates	with	
incident	MI	events,	 individuals	with	prevalent	MI	events	 (n	=	147)	and	missing	data	and	outliers	 in	study	variables	 (n	=	110)	were	
removed	 leaving	 complete	 data	 for	 7346	 individuals	 and	 305	 incident	 MI	 events	 for	 the	 analysis.	 Traditional	 risk	 factors	 (TRF)	
included	age,	 sex,	geographical	 region,	diabetes,	mean	arterial	blood	pressure,	blood	pressure	 treatment,	 smoking,	 log	BMI,	 total	
cholesterol,	 log	TG,	 lipid	 lowering	 treatment.	HDL-C;	high-density	 lipoprotein	cholesterol	 concentration,	apoA1;	apolipoprotein	A1	
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concentration,	TG;	 triglyceride	concentration,	HDL-P;	 total	high-density	 lipoprotein	particle	 concentration	 (a	 sum	of	 the	 individual	
HDL	subclass	particle	concentrations).		
Traditional	 risk	 factors	 (TRF)	 included	 age,	 sex,	 geographical	 region,	 diabetes,	 mean	 arterial	 blood	 pressure,	 blood	 pressure	
treatment,	smoking,	log	BMI,	total	cholesterol,	log	TG,	lipid	lowering	treatment.	
HDL-CEC;	NMR-based	HDL-mediated	cholesterol	efflux	estimate,	HDL-C;	high-density	 lipoprotein	cholesterol	concentration,	apoA1;	
apolipoprotein	A1	concentration,	TG;	triglyceride	concentration,	HDL-P;	total	high-density	lipoprotein	particle	concentration	(a	sum	
of	the	individual	HDL	subclass	particle	concentrations).	
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Supplemental	Table	5:	Comparison	of	association	of	HDL-CEC	with	incident	vascular	disease	end	points	between	FINRISK97		and	
Rohatgi	et	al.	(1)		and	Saleheen	et	al.	(2)		
	 	 	 In-vitro	assays	 NMR-based	
	
	
Results	
by	
Adjustments	
	
Rohatgi	et	al.	(1)	
HR	(95%	CI)		
Saleheen	et	al.	(2)	
OR	(95%	CI)		
FINRISK97	
HR	(95%	CI)	
Association	of	HDL-CEC	with	risk	of	myocardial	infraction	and	coronary	hearth	disease	
																																																																																																																														MI																																	CHD																																								CHD	
																																																																																																													(events=30;	n=2,416)	(cases=1,745;	controls=1,749)	(events=574;	n=7,290)																												
	 4th	vs	1st	
quartile	
none	 0.59	(0.23–1.49)	 	 0.63	(0.50-0.80)		
	 TRF	+	HDL-C+	HDL-P	 0.44	(0.17–1.18)a	 	 0.72	(0.56-0.92)a	
	 3rd	vs	1st	
tertile	
none	 	 0.58	(0.48–0.71)	 0.59	(0.47-0.72)d		
	 TRF	 	 0.58	(0.47–0.71)b	 0.61	(0.49-0.76)b,d	
	 TRF	+	HDL-C	 	 0.64	(0.51–0.80)b	 0.64	(0.51-0.80)b,d	
	 TRF	 	 0.48	(0.36–0.64)b,c	 0.61	(0.49-0.76)b,d	
	 TRF	+	apoA1	 	 0.50	(0.38–0.67)b,c	 0.62	(0.50-0.77)b,d	
	 	 TRF	+	HDL-C+	HDL-P	+apoA1	 	 	 0.65	(0.51-0.83)b,d	
	 Per	1-SD	
higher		
HDL-CEC	
none	 	 0.70	(0.64–0.78)	 0.81	(0.75-0.89)e	
	 TRF	 	 0.78	(0.70–0.87)b	 0.83	(0.76-0.90)b,e	
	 TRF	+	HDL-C	 	 0.80	(0.70–0.90)b	 0.84	(0.77-0.92)b,e	
	 TRF	+	apoA1	 	 0.72	(0.51-0.93)b	 0.84	(0.77-0.91)b,e	
	 TRF	+	HDL-C+	HDL-P	+apoA1	 	 	 0.85	(0.78-0.93)b,e	
Association	of	HDL-CEC	with	risk	of	cardiovascular	disease	
																																																																																																																											CVD																																																																																CVD	
																																																																																																																	(events=172;	n=2,416)																																									(events=789;	n=7,231)	
	 4th	vs	1st	
quartile	
none	
TRF	+	HDL-C+	HDL-P	
TRF	+	HDL-C+	HDL-P	+	apoA1	
0.52	(0.34-0.80)	
0.42	(0.27-0.65)a	
	 0.71	(0.59-0.86)	
0.78	(0.63-0.96)a	
0.79	(0.64-0.98)a	
	
	
	
	
	
	
	
	 	
Hazard	ratio	(HR)	for	HDL-CEC	was	calculated	by	Cox	proportional-hazard	model	by	quartiles,	tertiles	or	as	continuous	measure	(per	
1-SD	higher	HDL-CEC).	HR	 for	quartiles	and	 tertiles	are	 shown	 for	comparison	of	 top	per	bottom.	MI;	myocardial	 infraction,	CHD;	
coronary	artery	disease,	and	CVD;	cardiovascular	disease.	
In	FINRISK97	data	triglyceride	level	and	body-mass	index	were	log-transformed	and	alcohol	consumption	was	log1p-transformed	(see	
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methods	for	details).	
aTRF	from	Rohatgi	et	al.	 (1)	 included	age,	sex,	race,	presence	or	absence	of	diabetes,	presence	or	absence	of	hypertension,	status	
with	regard	to	current	smoking,	body-mass	index,	total	cholesterol	level,	log-transformed	triglyceride	level,	and	status	with	regard	to	
a	history	of	statin	use.	In	FINRISK97	adjustment	for	status	of	hypertension	and	statin	use	were	not	possible	and	instead	mean	arterial	
blood	pressure,	blood	pressure	treatment	and	status	with	regard	to	lipid	lowering	treatment	were	used.	In	addition,	analyses	were	
adjusted	for	geographical	region.	
bTRF	 from	 Saleheen	 et	 al.	 (2)	 included	 age,	 sex,	 history	 of	 diabetes,	 history	 of	 hypertension,	 cigarette	 use,	 alcohol	 intake,	 BMI,	
waist:hip	ratio,	LDL	cholesterol	concentration,	log-triglyceride	concentration.	In	FINRISK97	adjustment	for	status	of	hypertension	and	
cigarette	use	were	not	possible	and	instead	mean	arterial	blood	pressure,	blood	pressure	treatment	and	status	with	regard	current	
smoking	were	used.	In	addition,	analyses	were	adjusted	for	geographical	region	and	status	with	regard	to	lipid	lowering	treatment.	
HDL-CEC;	NMR-based	HDL-mediated	cholesterol	efflux	estimate,	HDL-C;	high-density	 lipoprotein	cholesterol	concentration,	apoA1;	
apolipoprotein	A1	concentration,	TG;	triglycerides	concentration,	HDL-P;	total	high-density	lipoprotein	particle	concentration	(a	sum	
of	the	individual	HDL	subclass	particle	concentrations).	
cSubstudy	to	analyze	association	of	HDL-CEC	and	apoA1	with	CHD	risk	mutually	adjusted	for	each	other.	
In	each	analysis	set	up,	complete	cases	with	all	variables	were	used	and	therefore	numbers	of	subject	with	incident	events	are	not	
identical.	
d528	events,	en	=	6,874;	529	events.	
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Supplemental	Table	6:	Correlation	of	HDL-CEC	with	clinical	variables.	
Variable	 Rohatgi	et	al.	
(1)			
	
Saleheen	et	
al.	(2)	
FINRISK97	
(95%	CI)	
HDL-C	concentration	 0.07*	 0.40***	 0.28	(0.25,030)***	
HDL	particle	size	 0.02	 -	 0.31	(0.29,0,33)***	
Total	HDL	particle	concentration	 0.15*	 -	 0.13	(0.10,0.15)***	
Apo	A-I	concentration	 -	 0.22***	 0.21	(0.18,0.23)***	
Total	C	concentration	 0.15*	 0.18***	 0.13	(0.11,0.16)***	
LDL-C	concentration	 0.10*	 0.05**	 0.09	(0.06,0.11)***	
ApoB	concentration	 -	 0.03	 -0.03	(-0.05,-0.01)**	
Triglycerides	concentration	 0.05	 –0.02	 -0.09	(-0.12,-0.07)***	
Age	 -	 0.06	 0.09	(0.07,0.11)***a	
Systolic	blood	pressure	 -	 0.02	 0.05	(0.03,0.08)***	
Diastolic	blood	pressure	 -	 0.02	 0	(-0.02,0.02)	
Waist	to	hip	ratio	 0.02	 –0.08***	 -0.07	(-0.09,-0.05)***	
Body	mass	index	 −0.02	 –0.06**	 -0.09	(-0.11,-0.07)***	
Alcohol	consumption	 -	 0.12***c	 0.06	(0.04,0.09)***b	
Sex	 -	 0.24*e	 0.20	(0.18,0.22)***d,e	
Type	2	diabetes	 -	 –0.18***	 0.03	(0.00,0.05)*	
Smoking	 -	 0	 0.00	(-0.03,0.02)	
Rohatgi	et	al.	(1);	Data	are	spearman	correlation	coefficients.	
Saleheen	et	al.	(2);	Data	are	analysed	by	linear	regression	adjusted	for	age	and	sex.	
FINRISK97;	Data	are	spearman	correlation	coefficients	adjusted	for	age	and	sex;	n	=	7,370,	df	=	
7,368.	
“-“	Denotes	that	a	correlation	coefficient	was	not	reported.		
aAdjusted	for	sex	only	
bAverage	alcohol	consumption	per	week	(g)	during	last	12	months.	
cAlcohol	consumption	(units	per	week)	
dAdjusted	for	age	only.	
eassociation	for	female	sex.	
***P	<	0.001	
**P	<	0.01	
*P	<	0.05	
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Supplemental	Table	7:	Clinical	variables	according	to	HDL-CEC	quartiles	in	FINRISK97	
Variable	 Quartile	1	
(n	=	1859)	
Quartile	2	
(n	=	1844)	
Quartile	3	
(n	=	1839)	
Quartile	4	
(n	=	1827)	
HDL-CEC	(%)	 19.8	(19.1-20.3)					 21.3	(21.0-21.5)						 22.5	(22.2-22.9)						 25.0	(24.1-26.4)					
HDL-C	concentration	(mg/dl)b	 52.2	(45.6-59.9)						 58.8	(51.0-67.3)	 64.6	(55.3-74.2)						 64.6	(53.8-76.6)						
HDL	particle	size	(nm)	 10.0	(9.9-10.2)						 10.2	(10.0-10.3)						 10.3	(10.1-10.5)						 10.3	(10.1-10.5)	
Total	HDL	particle	concentration	(µmol/l)	 7.96	(7.13-8.74)						 8.33	(7.50-9.22)						 8.74	(7.84-9.61						 8.58	(7.49-9.72)						
Apo	A-I	concentration	(g/l)	 1.48	(1.36-1.59						 1.55	(1.44-1.68)						 1.63	(1.49-1.77)						 1.61	(1.45-1.80)						
Total	C	concentration	(mg/dl)b	 197	(170-225)						 200	(173-227)						 204	(176-232)						 212	(184-244)						
LDL-C	concentration	(mg/dl)b	 72.3	(57.2-87.4)						 71.5	(56.1-86.6)						 71.2	(55.7-87.4)						 76.6	(61.1-93.2)						
ApoB	concentration	(g/l)	 1.01	(0.86-1.18)			 0.96	(0.81-1.13)			 0.95	(0.79-1.11)			 0.97	(0.81-1.17)				
Triglycerides	concentration	(mg/dl)c	 118.7	(88.6-161.2)						 96.5	(71.7-132.9)						 89.5	(64.7-127.5)						 101.0	(74.4-146.1)						
Age	(years)	 48.2	(37.8-58.9)						 45.8	(35.6-56.8)						 47.4	(36.1-58.2)						 50.7	(40.3-61.1)						
Systolic	blood	pressure	(mm	Hg)	 134	(123-149)									 131	(120-145)									 132	(120-146)									 137	(123-153)							
Diastolic	blood	pressure	(mm	Hg)	 83.0	(76.0-91.0)						 81.0	(74.0-89.0)						 81.0	(74.0-88.8)						 83.0	(75.0-90.0)						
Waist	to	hip	ratio	 0.90	(0.83-0.96)			 0.86	(0.79-	0.93)			 0.85	(0.77-0.92)			 0.84	(0.78-0.92)				
Body	mass	index	 27.0	(24.4-29.8)						 25.8	(23.3-28.5)						 25.4	(22.9-28.2)						 26.0	(23.3-29.3)	
Alcohol	consumptiona	 26.7	(3.8-84.7)							 26.4	(4.8-76.6)							 23.8	(3.7-68.5)							 22.8	(3.2-77.1)							
Women,	%	 35				 47				 55		 64			
Type	2	diabetes,	%	 6.1	 4.2					 5.2					 7.2				
Smoking,	%	 24				 26				 24			 21				
Data	are	median	(25th	and	75th	percentiles)	or	percentage,	when	appropriate.	
aAverage	alcohol	consumption	during	last	12	months.	
bTo	get	from	mg/dl	to	mmol/l	multiply	by	0.02586	
cTo	get	from	mg/dl	to	mmol/l	multiply	by	0.01129	
n;	number	of	subjects.	
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